3-acetoxy-4-methoxy-5-nitro-benzoic acid | 80547-88-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-acetoxy-4-methoxy-5-nitro-benzoic acid
• 英文别名: 3-Acetoxy-4-methoxy-5-nitro-benzoesaeure；Acetyl-5-nitro-isovanillinsaeure；3-acetyloxy-4-methoxy-5-nitrobenzoic acid
• CAS: 80547-88-2
• 化学式: C₁₀H₉NO₇
• 分子量: 255.184
• InChiKey: HHULPMAOMKRANK-UHFFFAOYSA-N

物化性质

• 沸点：
  397.7±42.0 °C(Predicted)
• 密度：
  1.454±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  119
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-acetoxy-4-methoxy-5-nitro-benzoic acid 生成 3-hydroxy-4-methoxy-5-nitrobenzoic acid
  参考文献：
  名称：

  Klemenc, Monatshefte fur Chemie, 1914, vol. 35, p. 95

  摘要：

  DOI：
• 作为产物：
  描述：

  3-acetoxy-4-methoxybenzoic acid 在 硝酸 作用下， 生成 3-acetoxy-4-methoxy-5-nitro-benzoic acid
  参考文献：
  名称：

  A new exhalite type—siderite-sericite chert formed in fault-controlled lacustrine basin

  摘要：

  On the basis of geological, fabric, lithographical and mineralogical study, a new exhalite type, called 'siderite-sericite chert' according to its mineral assemblage, was reported for the first time. It was formed in a fault-controlled lacustrine basin and closely associated with sulfide ore characteristic of complex metal assemblage of Sn-Ag-Cu-Pb-Zn. Its geological setting, mineral assemblage, as well as associated ores are quite unique, and therefore worthy of detailed research. In the Dajing deposit, Linxi County, Inner Mongolia, it is this very exhalite that is regarded as a kind of acidic subvolcanic dike till now, and because of this, a genetic model of hydrothermal epigenetic filling by subvolcanic fluid prevails over the Dajing deposit. It is demonstrated again that any geochemical study might be senseless without support of detailed geological and lithographical investigations. This is of particular importance at the present time when one is readily confused by various modern techniques.

  DOI：

  10.1007/bf02906864

文献信息

• [EN] ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS FUSIONNÉS D'ACIDE CYCLOPENTANE-CARBOXYLIQUE À SUBSTITUTION ACYLAMINO, ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2009135590A1

  公开（公告）日：2009-11-12

  The present invention relates to compounds of the formula (I), wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.

  本发明涉及具有式(I)的化合物，其中A，Y，Z，R3至R6，R20至R22和R50具有权利要求中指出的含义，它们是有价值的药物活性化合物。具体而言，它们是内皮分化基因受体2（Edg-2，EDG2）的抑制剂，该受体可被溶血磷脂酸（LPA）激活，也被称为LPA1受体，并且可用于治疗例如动脉粥样硬化、心肌梗死和心力衰竭等疾病。本发明还涉及制备式(I)化合物的方法、它们的使用以及包含它们的药物组合物。
• ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：SCHAEFER Matthias

  公开号：US20110152290A1

  公开（公告）日：2011-06-23

  The present invention relates to compounds of the formula I, wherein A, Y, Z, R 3 to R 6 , R 20 to R 22 and R 50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA 1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及式I的化合物，其中A、Y、Z、R3至R6、R20至R22和R50具有所述权利要求中指示的含义，这些化合物是有价值的药物活性化合物。具体来说，它们是内皮分化基因受体2（Edg-2，EDG2）的抑制剂，该受体被溶血磷脂酸（LPA）激活，也称为LPA1受体，可用于治疗动脉粥样硬化、心肌梗塞和心力衰竭等疾病。本发明还涉及制备式I化合物的方法、它们的用途以及包含它们的药物组合物。
• Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
  申请人：Schaefer Matthias

  公开号：US08362073B2

  公开（公告）日：2013-01-29

  The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及公式I的化合物，其中A，Y，Z，R3至R6，R20至R22和R50具有所述索引中指示的含义，它们是有价值的药物活性化合物。具体来说，它们是内皮分化基因受体2（Edg-2，EDG2）的抑制剂，该受体被溶血磷脂酸（LPA）激活，也称为LPA1受体，对于治疗动脉粥样硬化、心肌梗死和心力衰竭等疾病有用。本发明还涉及制备公式I化合物的方法、它们的使用以及包含它们的药物组合物。
• Klemenc, Monatshefte fur Chemie, 1914, vol. 35, p. 95
  作者：Klemenc

  DOI：——

  日期：——
• BORCHARDT, R. T.;HUBER, J. A., J. MED. CHEM., 1982, 25, N 3, 321-323
  作者：BORCHARDT, R. T.、HUBER, J. A.

  DOI：——

  日期：——